ResearcherInsermActive in the last 2 years
Denis Pezet
Matched on ORCID iD 0000-0001-9416-2876; OpenAlex author ID A5023325144. Sources: OpenAlex.
Their work
- Papers
- 8 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 33
2013: 1 paper · 2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 2 papers
Papers 8
- Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer. Co-author DOI 10.1093/oncolo/oyae079↗
- French multi-institutional cost-effectiveness analysis of gemcitabine plus nab-paclitaxel versus gemcitabine alone as second-line treatment in metastatic pancr… Co-author DOI 10.1177/17588359241259635↗
- TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer. Co-author DOI 10.1007/s00280-019-03807-4↗
- Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study. Co-author DOI 10.1177/1756284819878660↗
- Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. Co-author DOI 10.1038/s41416-018-0246-z↗
- Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer. Co-author DOI 10.1093/annonc/mdw607↗
- Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile? Last author DOI 10.1186/1477-7819-12-347↗
- Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic canc… Co-author DOI 10.1093/annonc/mdt066↗
Closest collaborators
The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Johan Gagnière · 2 shared papers, 2014–2024 · strength 0.26
- A Demazière · 1 shared paper, 2024 · strength 0.21
- G. Deplanque · 3 shared papers, 2017–2019 · strength 0.20
- Paper TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancre… DOI 10.1007/s00280-019-03807-4↗
- Paper Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. DOI 10.1038/s41416-018-0246-z↗
- Paper Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pan… DOI 10.1093/annonc/mdw607↗
- Teresa Mercade Macarulla · 3 shared papers, 2013–2019 · strength 0.17
- Paper TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancre… DOI 10.1007/s00280-019-03807-4↗
- Paper Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. DOI 10.1038/s41416-018-0246-z↗
- Paper Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previous… DOI 10.1093/annonc/mdt066↗
- Karim Adnane Benhadji · 2 shared papers, 2018–2019 · strength 0.14
- Paper TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancre… DOI 10.1007/s00280-019-03807-4↗
- Paper Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. DOI 10.1038/s41416-018-0246-z↗
- Josep M. Tabernero · 2 shared papers, 2018–2019 · strength 0.14
- Paper TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancre… DOI 10.1007/s00280-019-03807-4↗
- Paper Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. DOI 10.1038/s41416-018-0246-z↗
- Rocio García‐Carbonero · 2 shared papers, 2018–2019 · strength 0.14
- Paper TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancre… DOI 10.1007/s00280-019-03807-4↗
- Paper Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. DOI 10.1038/s41416-018-0246-z↗
- Davide Melisi · 2 shared papers, 2018–2019 · strength 0.14
- Paper TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancre… DOI 10.1007/s00280-019-03807-4↗
- Paper Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. DOI 10.1038/s41416-018-0246-z↗
- Anne‐Laure Pointet · 1 shared paper, 2019 · strength 0.08
- Francesca Simionato · 1 shared paper, 2019 · strength 0.08
- Jean–Marc Phelip · 1 shared paper, 2019 · strength 0.08
- Isabelle Trouilloud · 1 shared paper, 2019 · strength 0.08
- Dominique Béchade · 1 shared paper, 2019 · strength 0.08
- Julien Taı̈eb · 1 shared paper, 2019 · strength 0.08
- Simon Pernot · 1 shared paper, 2019 · strength 0.08
- Nicolas Williet · 1 shared paper, 2019 · strength 0.08
- David Tougeron · 1 shared paper, 2019 · strength 0.08
- Ivelina Gueorguieva · 1 shared paper, 2018 · strength 0.07
- Helmut Oettle · 1 shared paper, 2018 · strength 0.07
- Peter James O'Dwyer · 1 shared paper, 2017 · strength 0.06
- Thomas R. Jeffry Evans · 1 shared paper, 2017 · strength 0.06
- Bohuslav Melichar · 1 shared paper, 2017 · strength 0.06
- Gyorgy Bodoky · 1 shared paper, 2017 · strength 0.06
- Alexander S. Rosemurgy · 1 shared paper, 2017 · strength 0.06
- Eric Van Cutsem · 1 shared paper, 2017 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.